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In addition to the B-cell derived Burkitt lymphoma and
the immunoblastomas of immunodefective patients,
most of the rare nasal NK lymphomas and about half of
the Hodgkin's lymphomas (HL) carry EBV. In the 2 latter
malignancies, the neoplastic cells are embedded in granu-
lation tissue (with evidence for the contribution of the
microenvironment to the maintenance of the disease).
Their viral expression pattern is similar, EBNA-1 and LMP-
1 pos and EBNA-2 neg (type II). In contrast to the EBV-
driven immunoblastomas, EBV cannot be held directly
responsible for the growth of these 2 malignancies that
also differ among themselves.
Hodgkin's lymphomas
The few existing HL derived cell lines are EBV negative.
When from one line a forcibly converted EBV positive
subline was established, it expressed EBNA-1 only (Type
I).LMP-1 could be induced by exposure to CD40L and IL-
4. Conceivably, the in vivo phenotype (Type II) is
imposed by the cytokines that abound in the granulation
tissue. According to one present view EBV is important in
the early stage of HL development, in that it rescues B lym-
phocytes with non functional Ig-rearrangements from
apoptosis.
Nasal NK/T lymphomas
Normal NK/T cells do not carry EBV receptors The mech-
anism of infection of the NK/T cells is not known. EBV
carrying cell lines exist and they express the Type II pat-
tern, corresponding thus to the in vivo phenotype. They
require IL-2 for in vitro proliferation. Conceivably IL-2
can be provided by activated T cells in vivo. Treatment
with cytokines (IL-10, IFN g) upregulates LMP-1 expres-
sion that leads to more efficient growth response to IL-2.
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